- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02709915
Effect of Meal Frequency and Timing on Insulin Dose and Clock Gene in Type 2 Diabetic Patients (Bdiet-6Mdiet)
Effect of Meal Frequency and Timing on Glycemic Control, Daily Insulin Dose Requirements and Clock Gene Expression in Uncontrolled Type 2 Diabetic Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Obese patients with type 2 diabetes (T2D) and insulin resistance (IR), often require sequential increments of total daily insulin dose (TDID). This causes weight gain, worsens IR, leading to further increase of TDID and persistent hyperglycemia. In these patients, weight loss (WL) and reduction of IR are mandatory in order to achieve glucose control with less TDID. Impaired clock gene (CG) expression is linked to obesity and IR in T2D and it was shown in animals and T2D patients treated with oral anti-hyperglycemic drugs, that WL diet with restricted meal timing to specific hours, restored CG expression and was more effective for WL and for reduction of hyperglycemia compared to isocaloric WL diet, (commonly recommended for T2D), consisting of small meals randomly distributed along the day.
The investigators hypothesized that in patients with uncontrolled T2D treated with insulin, a diet with large breakfast and lunch with small dinner (Bdiet) will enhance CG expression and will be more effective for WL and for achieving glycemic control and reduction of TDID, compared to an isocaloric diet with 6 small meals distributed evenly along the day (6Mdiet).
This will be a randomized parallel, open label clinical study. Thirty overweight and obese insulin-treated T2D patients with HbA1c>7.5% will be assigned to 12 weeks of 2 isocaloric diets: either Bdiet or 6Mdiet. HbA1c and CG mRNA expression in white blood cells and overall daily glycemia measured during 14 days, will be assessed before diet, after 14 days and at the end of the diet intervention. The TDID (first end point ) will be adjusted by physician, according to the results of self-monitoring of blood glucose on 3 consecutive days at baseline and before each of the visits.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wolfson Medical Center
-
Holon, Wolfson Medical Center, Israel, 58100
- Daniela Jakubowicz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- T2D patients with stable insulin treatment for at least 3 month preceding the study.
- HgA1c >7.5 %.
- Age > 30 years.
- BMI: 27-34 kg/m2.
- Treatment with antidiabetic drugs (i.e. metformin, DPP4 inhibitors, glinides) and GLP-1 analogs.
- Anti-hypertensive treatment will be allowed.
- Lipid-lowering medication.
Exclusion Criteria
- Type 1 diabetes.
- Major illnesses (liver, heart, kidney, infectious, neurological, psychiatric, immunological, active malignancy).
- Presently dieting.
- Change in weight of > 4.5 kg within 3 month prior to study onset.
- Night or rotating shift workers.
- Those who crossed more than 2 time zones during 2-week period prior to study onset.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Breakfast Diet (Bdiet)
The Bdiet will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
|
The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system.
The investigators will assess also the Clock Genes mRNA expression in white blood cells.
at baseline and after 12 weeks of diet intervention
Other Names:
The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks.
In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
Other Names:
|
|
Active Comparator: 6 small meals diet (6Mdiet)
The 6Mdiet will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% each of the three snacks.
|
The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system.
The investigators will assess also the Clock Genes mRNA expression in white blood cells.
at baseline and after 12 weeks of diet intervention
Other Names:
The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks.
In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insulin Dose
Time Frame: Baseline, 2 week and at 12 weeks
|
The effects of two diets (Bdiet and 6Mdiet) will be compared on their efficacy on total insulin dose reduction measured at baseline, after 2 weeks and at the end (12 weeks) of both diet interventions
|
Baseline, 2 week and at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c
Time Frame: Baseline, 2 weeks and at 12 weeks
|
The effect of the two diets (Bdiet and 6Mdiet) will be compared on the efficacy on the reduction of HbA1c measured at baseline, after 2 weeks and at the end (12 weeks) of both diet interventions
|
Baseline, 2 weeks and at 12 weeks
|
|
Overall Glycemia
Time Frame: Baseline, 2 week and at 12 weeks
|
The effect of the two diets on all-day glycemia will be assessed with continuous blood monitoring system at baseline, after 2 weeks and after 12 weeks of the two diet intervention
|
Baseline, 2 week and at 12 weeks
|
|
Clock Gene mRNA expression
Time Frame: Baseline, 2 week and at 12 weeks
|
The measurement of mRNA expression of clock gene in circulating white blood cells will be assessed at baseline, after 2 weeks and after 12 weeks of the two diet intervention
|
Baseline, 2 week and at 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Weight
Time Frame: Baseline, 2 week and at 12 weeks
|
The measurement of body weight assessed at baseline, after 2 weeks and after 12 weeks of the two diet intervention
|
Baseline, 2 week and at 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julio Wainstein, MD, Wolfson Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 0233-15-WOMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of MiamiSexual Medicine Society of North America Inc.Not yet recruitingType 2 Diabetes | Type 2 Diabetes (T2DM)United States
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsRecruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
University of PennsylvaniaNational Institute on Aging (NIA); American Heart AssociationRecruitingType 2 Diabetes Mellitus | Type 2 Diabetes | Type II Diabetes Mellitus | Pre-diabetes | Pre-diabetic | Type II Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2DM) | Pre-diabetic StateUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
Clinical Trials on Breakfast Diet (Bdiet)
-
Westlake UniversityCompletedHealthy | Overweight and ObesityChina
-
Tel Aviv UniversityUnknownObesity | Type 2 DiabetesIsrael
-
Melike Nur EroğluCompletedObesity | Overweight | Circadian Rhythm | Meal Timing | Appetite Regulation | Metabolic HealthTurkey
-
Westlake UniversityThe Third People's Hospital of HangzhouRecruiting
-
Manchester Metropolitan UniversityCargill; The University of BathNot yet recruitingHealthy Adult Male | Carbohydrate Metabolism | Hepatic Glycogen Storage
-
Hacettepe UniversityRecruitingType 2 Diabetes Mellitus | AppetiteTurkey
-
Texas Tech UniversityAmerican Egg BoardCompleted
-
Tel Aviv UniversityUnknown
-
Texas Tech UniversityAmerican Egg BoardCompleted